Enhanced Procoagulant Activity on Blood Cells after Acute Ischemic Stroke

Yao, Zhipeng; Wang, Lixiu; Wu, Xiaoming; Zhao, Lu; Chi, Chunling; Guo, Li; Tong, Dongxia; Yang, Xiaoyan; Dong, Zengxiang; Deng, Ruijuan; Novakovic, Valerie A.; Thatte, Hemant S.; Bi, Yang; Tian, Ye; Shi, Jialan; Zhou, Jin; Kou, Junjie; Hu, Shaoshan

doi:10.1007/s12975-016-0501-7

Cited by 31 publications

(27 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been proposed that, the levels of adherent factors including VCAM-1, ICAM-1 and VE-caderin were increased mainly in post-capillary venules after stroke, together with leukocyte trafficking receptors (Alexander et al, 2013; Altura et al, 2002; Ishikawa et al, 2004). Platelets, in addition, contribute significantly to the formation of microclots, which can be reversed through inhibition of integrin aIIbb3 (Abumiya et al, 2000; Xu et al, 2016; Yao et al, 2017). Fibrin provides frame construction for blood cells to fill in, helps stiff clots to develop, and adhere and deposit in the microvessels (Jeanneret and Yepes, 2016).…”

Section: The Importance Of Identifying Cerebral Venous System Changesmentioning

confidence: 99%

Cerebral venous collaterals: A new fort for fighting ischemic stroke?

Tong

Guo

et al. 2018

Progress in Neurobiology

View full text Add to dashboard Cite

Stroke therapy has entered a new era highlighted by the use of endovascular therapy in addition to intravenous thrombolysis. However, the efficacy of current therapeutic regimens might be reduced by their associated adverse events. For example, over-reperfusion and futile recanalization may lead to large infarct, brain swelling, hemorrhagic complication and neurological deterioration. The traditional pathophysiological understanding on ischemic stroke can hardly address these occurrences. Accumulating evidence suggests that a functional cerebral venous drainage, the major blood reservoir and drainage system in brain, may be as critical as arterial infusion for stroke evolution and clinical sequelae. Further exploration of the multi-faceted function of cerebral venous system may add new implications for stroke outcome prediction and future therapeutic decision-making. In this review, we emphasize the anatomical and functional characteristics of the cerebral venous system and illustrate its necessity in facilitating the arterial infusion and maintaining the cerebral perfusion in the pathological stroke content. We then summarize the recent critical clinical studies that underscore the associations between cerebral venous collateral and outcome of ischemic stroke with advanced imaging techniques. A novel three-level venous system classification is proposed to demonstrate the distinct characteristics of venous collaterals in the setting of ischemic stroke. Finally, we discuss the current directions for assessment of cerebral venous collaterals and provide future challenges and opportunities for therapeutic strategies in the light of these new concepts.

show abstract

Section: The Importance Of Identifying Cerebral Venous System Changesmentioning

confidence: 99%

Cerebral venous collaterals: A new fort for fighting ischemic stroke?

Tong

Guo

et al. 2018

Progress in Neurobiology

View full text Add to dashboard Cite

show abstract

“…The pathogenesis of cerebrovascular diseases in SLE patients with elevated serum MFG‐E8 levels is unknown. Interestingly, a recent study found that PS exposure on erythrocytes, platelets and leukocytes was significantly elevated in patients with acute ischemic stroke, and the addition of MFG‐E8 to blood cells from acute ischemic stroke patients delayed coagulation time by approximately 20% and blocked the generation of blood coagulation factor Xa and thrombin by approximately 50%, suggesting that MFG‐E8 has therapeutic anticoagulation potential for ischemic cerebral infarction. Additionally, some reports using animal models of cerebral infarction showed that MFG‐E8 deficiency resulted in a larger infarct size and that administration of MFG‐E8 reduced infarct size .…”

Section: Discussionmentioning

confidence: 99%

Elevated serum MFG‐E8 level is possibly associated with the presence of high‐intensity cerebral lesions on magnetic resonance imaging in patients with systemic lupus erythematosus

Kishi

Motegi

Ishikawa

2017

The Journal of Dermatology

View full text Add to dashboard Cite

Human milk fat globule-EGF factor 8 (MFG-E8), also known as lactadherin, is a secreted glycoprotein that plays essential roles in the clearance of apoptotic cells and angiogenesis. It has been reported that serum MFG-E8 levels are higher in systemic lupus erythematosus (SLE) patients compared with in healthy controls; however, a previous study reported no correlation between serum MFG-E8 levels and SLE disease activity. The objective of this study was to assess serum MFG-E8 levels and their clinical associations in patients with SLE. Serum MFG-E8 levels in 49 Japanese patients with SLE, eight with cutaneous LE, and 28 healthy controls were examined. Serum MFG-E8 levels in SLE patients were significantly higher than those in cutaneous LE patients and healthy individuals. In addition, serum MFG-E8 levels were positively correlated with the SLE Disease Activity Index score, which reflects the disease activity of SLE. Notably, the frequency of the presence of high-intensity cerebral lesions on MRI in the SLE patients with elevated serum MFG-E8 levels was significantly higher than that in SLE patients with normal serum MFG-E8 levels. These findings suggest that elevated serum MFG-E8 levels may be associated with cerebrovascular diseases or neuropsychiatric SLE in patients with SLE, and that the measurement of serum MFG-E8 levels in SLE patients is useful for risk stratification of cerebrovascular disease or cerebrovascular diseaserelated neuropsychiatric SLE.

show abstract

“…The formation of intrinsic, extrinsic FXa and prothrombinase was detected with the method described previously with some modifications. 16 To evaluate the production of intrinsic FXa, cells were incubated with 1 nM factor IXa, 5 nM factor VIII, 0.2 nM thrombin, 130 nM factor X and 1.5 mM CaCl 2 in factor Xa buffer (TBS with 0.2% BSA) at RT for 5 min. The reaction was then stopped by the addition of EDTA to 7 mM final concentration.…”

Section: Intrinsic Extrinsic Fxa and Prothrombinase Assaysmentioning

confidence: 99%

Enhanced procoagulant activity of platelets after chemotherapy in non-small cell lung cancer

Kou

et al. 2017

Cancer Biology & Therapy

Self Cite

View full text Add to dashboard Cite

The procoagulant status of patients with non-small cell lung cancer (NSCLC) after chemotherapy is poorly characterized and the role of platelets in hypercoagulative state of NSCLC is unknown. The aim of this study was to evaluate the procoagulant activity (PCA) of platelets in NSCLC before and after chemotherapy. The subjects were 52 patients newly diagnosed with NSCLC. The patients had decreased clotting time compared with healthy subjects, and the thrombin-antithrombin complex increased 2.5-fold after chemotherapy. Platelets in the patients after chemotherapy had enhanced phosphatidylserine (PS) exposure, and shortened coagulation time as well as increased thrombin and fibrin formation of platelets compared with those before chemotherapy. Platelet-derived microparticles increased 2-fold at day 1 and peaked at day 2 post-chemotherapy. Treatment of cisplatin in vitro also resulted in upregulated intrinsic FXa and thrombin formation on platelets with a dose-dependent manner. Platelets treated with aspirin significantly decreased PCA. However, lactadherin blocked PS and inhibited the PCA approximately by 70%. Seven days after chemotherapy, PCA of platelets restored to the baseline as that before chemotherapy, indicating that within a week of chemotherapy patient platelets are highly procoagulant and effective intervention should be taken in case of thrombosis. Our results suggested that platelets after chemotherapy had elevated PCA and may contribute to the hypercoagulative state of NSCLC. Prophylactic anti-coagulant combined with anti-platelet therapy may play an inhibitory role in thrombotic complications in NSCLC.

show abstract

Enhanced Procoagulant Activity on Blood Cells after Acute Ischemic Stroke

Cited by 31 publications

References 28 publications

Cerebral venous collaterals: A new fort for fighting ischemic stroke?

Cerebral venous collaterals: A new fort for fighting ischemic stroke?

Elevated serum MFG‐E8 level is possibly associated with the presence of high‐intensity cerebral lesions on magnetic resonance imaging in patients with systemic lupus erythematosus

Enhanced procoagulant activity of platelets after chemotherapy in non-small cell lung cancer

Contact Info

Product

Resources

About